ESR1 and breast carcinoma: Compounds 23a–23d (Figure 8), reported by Latif et al. (2020), were screened for their cytotoxic activity against the estrogen receptor (ER)-positive breast cancer cell line MCF-7 and the triple-negative breast cancer (TNBC) MDA-MB-231 cell line [66].